Cerevel Therapeutics Holdings Inc

NASDAQ:CERE   3:59:55 PM EDT
26.94
+0.03 (+0.11%)
Earnings Announcements

Cerevel Therapeutics Reports First Quarter 2022 Financial Results And Business Updates

Published: 05/10/2022 10:42 GMT
Cerevel Therapeutics Holdings Inc (CERE) - Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates.
Cerevel Therapeutics Holdings - on Track to Initiate Two Parallel Adequately-powered Phase 2 Trials of Emraclidine in Schizophrenia by Mid-year 2022.
Cerevel Therapeutics Holdings - Cash, Cash Equivalents and Marketable Securities Are Expected to Continue to Support Operations Into 2024.
Cash, Cash Equivalents and Marketable Securities As of March 31, 2022, Were $550.9 Million.
Qtrly Loss per Share $0.46.
Q1 Earnings per Share View $-0.43 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.48

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.49

More details on our Analysts Page.